Fanconi Anemia Signaling and Cancer

FA is a rare human genetic disease, sometimes called a chromosomal disorder syndrome (different from Fanconi syndrome, a kidney disorder). Mutations in FA genes are considered as ‘mutator mutations’, because of their important roles in DNA damage repair. This feature may be a fundamental mechanism underlying ‘acquired tumor resistance’. Translesion DNA polymerases appear to be regulated by FA signaling, and may also be important for tumor sensitivity/resistance. To date, it remains unclear how many FA complementation groups exist, because there are FA cases that cannot be assigned to any of the 22 complementation groups presently known. Nonmonoubiquitinated FANCD2 is a major molecular defect underlying many complementation groups. The extremely high cancer incidence associated with patients suffering from a rare human genetic disease, Fanconi anemia (FA), demonstrates the importance of FA genes. Over the course of human tumor development, FA genes perform critical tumor-suppression roles. In doing so, FA provides researchers with a unique genetic model system to study cancer etiology. Here, we review how aberrant function of the 22 FA genes and their signaling network contributes to malignancy. From this perspective, we will also discuss how the knowledge discovered from FA research serves basic and translational cancer research. The extremely high cancer incidence associated with patients suffering from a rare human genetic disease, Fanconi anemia (FA), demonstrates the importance of FA genes. Over the course of human tumor development, FA genes perform critical tumor-suppression roles. In doing so, FA provides researchers with a unique genetic model system to study cancer etiology. Here, we review how aberrant function of the 22 FA genes and their signaling network contributes to malignancy. From this perspective, we will also discuss how the knowledge discovered from FA research serves basic and translational cancer research. ability to gain resistance after treatment with the drugs, resulting from mutation of genes involved in normal physiological processes and cellular structures, from the acquisition of foreign resistance genes, or from a combination of these two mechanisms. accumulated studies indicate that FA signaling plays increasingly important roles in ATR-initiated cellular responses. In this review, we would like to emphasize the importance, and considered such signaling as ‘ATR–FA signaling’. mutations in the human RecQ helicase. reduction of effectiveness of a medication by developing a mechanism against the drug by the body or by bacteria in the process of medication. Fanconi anemia (FA) is a rare genetic disease characterized by chromosomal instability, hypersensitivity to DNA crosslinking agents, defective DNA repair, severe bone marrow failure, cancer susceptibility, and many congenital defects. To date, 22 FA genes have been identified. Germline mutation in any of these 22 genes confers FA, and the corresponding wild-type gene can complement the phenotypes shown. Therefore, each FA group resulting from a specific mutated FA gene is called a complementation group. all groups of FA patients display similar clinical symptoms as well as similar molecular and cellular defects, suggesting that all FA gene-encoded proteins act in one common signaling pathway, namely, the FA pathway or the FA-BRCA pathway, given the fact that several FA portions are breast cancer-susceptibility gene (BRCA)-related proteins. the ubiquitin conjugating enzyme E2-UBE2T Variant of FA protein L – FANCL mutated proteins not only lost the functions performed by the corresponding wild-type proteins but also obtained new functions, called gain of function. the process by which patients or relatives at risk of an inherited disorder are advised of the consequences and nature of the disorder, the probability of developing or transmitting it, and the options for treatment and management of the disorder in all supportive aspects. a variant of the H2A protein family. a surgery to remove all breast tissue from a breast as a way to treat or prevent breast cancer. mutator phenotype refers to the increase in mutation rate of cancer cells, which results from the mutated genes, and the correspondingly encoded wild-type proteins play important roles in the maintenance of genome stability. a surgical procedure to remove one or both parts of ovaries. a term for Cisplatin and its analogs, a common type of chemotherapeutic drugs that can crosslink DNA. a model that proposes the customization of health care with medical decisions, practices, or products being tailored to the individual patient. DNA repair protein REV1 a systemic cancer therapy is the treatment strategy in which drugs are spread throughout the body to treat cancer cells wherever they may be. the sum of all signaling transduction events, which are performed by any functional unit that contains one or more FA proteins. refers to a study of biology ending in −omics, such as genomics, proteomics, metabolomics. Omics aims at the collective characterization and quantification of pools of biological molecules that translate into the structure, function, and dynamics of an organism. a DNA damage tolerance process that allows the DNA replication machinery to replicate past DNA lesions. In many case, this damage-tolerance mechanism is error prone, and cell survival is often associated with an increased risk of mutagenesis and carcinogenesis. death of tumor cells after the treatment with chemotherapeutic drugs or others. the alternative promoter (P2) of p63 leads to deleted-transactivation domain (TA) isoforms phosphorylated histone variant.